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Abstract Cahtexin is a central component of the ‘quality 
control’ system in the endoplasmic retlcuhun (ER). Cahrexin 
binds to monoglycosylated oligosaccharides on incompletely 
folded soluble and membrane proteins in the lumen of the ER 
and prevents exit from the organelle. We have previously found 
that the ollgosaccharide transferase enzyme can add glycosyl 
moieties to a membrane protein when the acceptor site is as close 
as 12-13 residues away from the nearest transmembrane segment 
(J. Biol. Chem. 268,5798). We now show that cahtexln can bind 
to oligosaccharides located this close to the membrane, suggest- 
ing that its binding site is held at a similar distance from the 
membrane as is the active site of the ollgosaccharlde transferase. 
We further show that calnexin can bind efftciently to glycosy- 
lated but not to non-glycosylated forms of a bacterial inner 
membrane protein, suggesting that it does not have a general 
affinity for non-glycosylated proteins. 
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1. Introduction 
Calnexin is a type I membrane protein believed to be in- 
volved in the folding of both soluble and membrane proteins 
in the endoplasmic reticulum (ER) (for a review see [l]). Cal- 
nexin interacts with incompletely folded proteins through 
their partially deglycosylated, N-linked oligosaccharides 
[2,3]. Although calnexin preferentially interacts with monogly- 
cosylated oligosaccharides, the fact that some unglycosylated 
proteins can also interact with calnexin shows that N-linked 
glycans are not the only site of interaction [4-6]. Recent find- 
ings suggest that the oligosaccharide interaction is essential 
for the initial formation of the calnexin/glycoprotein complex, 
but that once this complex has formed the glycan is dispens- 
able and binding occurs through the polypeptide chain [7,8]. 
In addition, incorrectly folded, non-glycosylated proteins can 
form high-molecular-weight aggregates including calnexin in 
the ER [18]. 
We have previously shown that integral membrane proteins 
can only be glycosylated on asparagine residues located at 
least 12-13 residues away from the nearest transmembrane 
segment, suggesting that the active site of the oligosaccharyl 
transferase enzyme is positioned a certain distance above the 
lumenal surface of the ER membrane [12]. Since calnexin is 
also an integral membrane protein of the ER, we wanted to 
determine whether its glycan binding site was located as close 
to the membrane as the oligosaccharyl transferase active site, 
or whether N-glycans located too near a transmembrane seg- 
ment would not be able to bind to calnexin. 
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For this study, the E. coli inner membrane protein leader 
peptidase (Lep) [9] was chosen as a model protein (Fig. 1). 
Lep has previously been expressed in an in vitro transcription/ 
translation system and was shown to be correctly inserted into 
dog pancreas microsomes and glycosylated [lo]. Lep has also 
been expressed in BHK cells where the P2 domain is trans- 
located into the ER lumen and properly folded as assayed by 
disulphide bridge formation and glycosylation at a naturally 
occurring acceptor site for N-linked glycosylation (our unpub- 
lished data; cf. [17]). Lep thus behaves like an endogenous 
eukaryotic ER membrane protein when expressed in BHK 
cells. Further, since Lep is a prokaryotic protein, it has not 
evolved specific binding sites for calnexin and is thus an ideal 
model protein for studying the interaction between calnexin 
and proteins either with or without N-linked glycans. 
Our results show that calnexin can bind glycosylated wild 
type Lep but not a non-glycosylated mutant (Asn214 -+ Gln) in 
which the acceptor site for N-linked glycosylation has been 
destroyed. Another mutant with its only glycosylation site 
placed 13 amino acids from the H2 transmembrane domain 
can still interact with calnexin. This demonstrates that calnex- 
in can bind to N-linked glycans located very near the ER 
membrane and further that calnexin cannot bind a non- 
glycosylated prokaryotic membrane protein. 
2. Materials and methods 
2.1. Cell culture 
Baby hamster kidney 21 (BHK) cells were grown in Glasgow mini- 
mal essential medium (Gibco, BRL, Glasgow MEM (BHK-21), with 
L-glutamine, without tryptose phosphate broth) supplemented with 
10% tryptose phosphate broth, 5% fetal calf serum, 20 mM HEPES 
(4-(2-hydroxyethyl)-l-piperazineethanesulphonic acid pH 7.3) and 
2 mM glutamine. Penicillin (100 U/ml) and streptomycin (100 ng/ 
ml) were also added to media for passage of cells. Cells were incu- 
bated at 37°C and 5% CO*. Cells were grown in 35-mm dishes (about 
1 x 106 cells). 
2.2. DNA constructs 
Wild-type Lep and the Lep mutants used were originally cloned 
into pGEM1 and have been described in detail elsewhere [12,13]. 
Cloning of the Lep constructs into the Sernliki Forest Virus expression 
vector (SFVl) was carried out by PCR using the pGEM1 plasmids as 
templates. PCR primers were designed to create restriction sites flank- 
ing the Lep gene. 
The 5’-end primer GGGCGGATCCGGCGAATTCCACCAGC- 
CAGGGTTC and the 3’-end primer GCCTATCCCGGGCAAACG- 
TGAACGAAGATGG created a BamHI and SmaI site, respectively. 
The amplified Lep gene fragment was digested with BamHI and SmaI 
and inserted into the polylinker region of SFVI [14]. 
2.3. Transfection of cells 
Transcription of RNA from plasmid DNA was done in a 50 ~1 
mixture as described in [15]. 20 pl of the transcription reaction was 
used to transfect 5~ lo6 BHK cells by electroporation in a 0.4~cm 
cuvette (850 V/25 uF) [15]. Efficient transfection was achieved by 
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thoroughly suspending cells beforehand by trypsinisation and gentle 
mixing. After transfection the cells were diluted 20-fold with BHK 
medium, distributed into 35-mm plates and incubated at 37°C in a 
5% CO* atmosphere. 
2.4. Metabolic hbeliing of proteins 
For the labelling of one dish of cells approximately 50 pCi of 
[““Slmethionine (Amersham, specific activity > 37 TBq/mM, > 1000 
Ci/mM) was used. Labelling was carried out for different times in 500 
11 of MEM lacking methionine (Gibco, BRL, MEM with Earle’s 
salts, without L-glutamine and L-methionine). The incubation of cells 
in this medium was started 30 min before labelling, in order to pre- 
starve cells of methionine. Labelling was terminated by changing the 
medium to MEM containing IO times concentrated, unlabelled 
methionine. Chase in this medium was continued for different times. 
Transfected cells were labelled 7 h after electroporation. 
2.5. Preparation of‘ cell lysates and media 
After pulse chase, cells were put on ice, the medium was removed, 
and the cells were washed twice with cold PBS and solubilised with 
300 ~1 of HBS buffer (200 mM NaCl, 50 mM HEPES, pH 7.6) con- 
taining CHAPS (2%). PMSF (phenylmethylsulphonyl fluoride; 1 mM), 
aprotinin (5 &ml), and leupeptin (5 &ml) were added to prevent 
protein degradation. The lysate was incubated for 30 min at 4°C and 
centrifuged at 11 OOOxg for 10 min at 4°C. The supernatant was 
transferred to a fresh tube and diluted once with HBS buffer. Pansor- 
bin (50 1.11) was added and the lysate was incubated for 30 min at 4°C 
and then centrifuged at 11000 x g for 5 min. 
2.6. Immunoprecipitation and SDS-PAGE 
The supernatant was split into two and used for protein A-mediated 
immunoprecipitation using 2 ~1 of either anti-Lep or anti-calnexin 
antibody. Final precipitates were solubilised in 20 pl SDS gel sample 
buffer and applied onto a 10% acrylamide gel (Hoefer Mighty Small 
gel system). 
3. Results and discussion 
To analyse the interaction between calnexin and glycosy- 
lated, wild-type Lep, BHK cells expressing Lep were pulsed 
with [“5S]Met for 2 min and chased with non-radioactive Met 
for 2, 5, 30, 60 or 90 min. The cells were then lysed in CHAPS 
and precipitated with either a Lep or a calnexin polyclonal 
/ 
Asn2 14 
P2 
P C 
cyto plasm 
Pl 
v 
Fig. 1. Orientation of Lep in the ER membrane. The two hydro- 
phobic transmembrane segments Hl and H2, the cytoplasmic loop 
Pl, the large lumenal domain P2, and the Asnzl* glycosylation site 
are indicated. In the Lep mutant analyzed in Fig. 4, the H2 region 
(residues 59-80) was replaced by the sequence IK4L14VQsP, Asr? 
was changed to Gin, and an Asn-Ser-Thr acceptor site for N-linked 
glycosylation was inserted 13 residues downstream of the H2 trans- 
membrane segment [13]. 
Fig. 3. A non-glyosylated Lep mutant is not precipitated by calnex- 
in antibody. Cell lysates were immunoprecipitated with either a Lep 
(top panel) or a calnexin (bottom panel) polyclonal antibody. See 
Fig. 2 for details. 
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Fig. 2. Interaction between calnexin and wild-type Lep. Lep was ex- 
pressed in BHK cells and metabolically labelled for 2 min with 
[“5S]methionine. After a chase of 2, 5, 30, 60, or 90 min cells were 
lysed in CHAPS lysis buffer and the lysates were immunoprecipi- 
tated with either a Lep (top panel) or a calnexin (bottom panel) 
polyclonal antibody, and the samples were analysed by SDS-PAGE 
and autoradiography. 
antibody. Lep could be precipitated with the calnexin anti- 
body and the interaction was strongest after a 5-min chase 
(Fig. 2, bottom panel). At longer chase times, the intensity of 
the signal decreased, indicating a transient interaction between 
Lep and calnexin, as has also been observed for other glyco- 
proteins [16]. The dissociation was not due to protein degra- 
dation, since the intensity of the Lep signal in a Lep antibody 
precipitation was equally strong throughout the chase period 
(Fig. 2, top panel). The glycosylated protein remained sensi- 
tive to EndoH throughout a 3-h chase period and gave an 
ER-like staining in immunofluorescence (data not shown), 
suggesting that it did not reach the medial Golgi compart- 
ment. 
As a control, the same experiment was carried out with a 
Lep mutant where Asn214 was changed to Gln to prevent 
glycosylation. This mutant could not be precipitated with 
the calnexin antibody (Fig. 3). Further, when cell lysis was 
carried out by addition of the detergent NP-40 (1% final con- 
centration) that is more disruptive to protein-protein interac- 
tions than CHAPS [19], wild-type Lep could be efficiently 
precipitated by Lep antiserum but not by calnexin antiserum 
chase time (min) 
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(data not shown), demonstrating that Lep does not bind to wt mutant 
calnexin during the immunoprecipitation step. MN 77 + CST 
Having shown that calnexin can only interact with glycosy- 
lated Lep, it was of interest to determine whether calnexin can 
bind to a Lep mutant with its sole acceptor site for N-linked 
glycosylation located only 13 amino acids away from the H2 
transmembrane segment, i.e. at the minimal distance from the 
membrane required for efficient glycosylation by oligosacchar- 
yl transferase [12,13]. For this experiment, we chose a mutant 
where the H2 segment is composed of a stretch of 14 leucine 
residues and one valine (see legend to Fig. l), as the minimal 
glycosylation distance has been carefully determined for this 
construct [13]. As shown in Fig. 4, this mutant could also be 
precipitated with the calnexin antibody. In this case, the Lep- 
calnexin interaction persisted throughout the chase period, 
suggesting that the glycosylation may prevent proper folding 
of Lep. 
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Misfolding of the mutant molecules caused by the introduc- 
tion of the glycosylation site might expose new segments of 
the protein for binding to calnexin, bypassing the need for a 
glycan moiety. To rule this out, cells expressing the mutant 
were pretreated with castanospermine and pulse-chased in the 
presence of the drug. Castanospermine is a glucosidase inhib- 
itor and prevents the trimming of glucose residues from the 
core glycan [l I]. This treatment inhibits the binding of calnex- 
in to N-linked glycans since calnexin, at least preferentially, 
binds to monoglucosylated oligosaccharides [2,3,18]. As 
shown in Fig. 5 (top panel), the amount of mutant protein 
that could be precipitated with the calnexin antibody in cas- 
tanospermine-treated cells decreased drastically, indicating 
that the interaction between calnexin and the mutant protein 
was exclusively mediated by the glycosyl moiety. The same 
was true for wild-type Lep (Fig. 5, bottom panel). In both 
cases, the castanospermine-treated molecules had a slightly 
lower mobility, consistent with the block of glucose trimming 
caused by the drug. Similar result was obtain using tunicamy- 
tin, an inhibitor of N-linked glycosylations (data not shown). 
Fig. 5. The calnexin-Lep interaction is inhibited by castanospermine. 
Cells expressing wild-type or mutant Lep were pretreated for 150 
min with 1 mM castanospermine (CST), radiolabelled for 10 min, 
and chased for 5 min in the presence of the inhibitor. Untreated 
cells were used as a control (lanes 1 and 3). After cell lysis, the ly- 
sates were precipitated with either a Lep (top) or a calnexin (bot- 
tom) antibody. The slower mobility of the mutant compared to the 
wild-type protein is caused by the additional residues in and around 
the H2 segment in the mutant. 
sugars located very close to a transmembrane segment. It thus 
seems that calnexin and the oligosaccharyl transferase have 
co-evolved in such a way that calnexin can bind glycan moi- 
eties located as near to the ER membrane as the oligosacchar- 
yl transferase can put them. 
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In conclusion, our results show that two glycosylated forms 
of the bacterial inner membrane protein Lep can bind to 
calnexin in the ER, whereas a non-glycosylated form cannot. 
Thus, calnexin has no or little affinity for a non-glycosylated 
prokaryotic protein. Further, calnexin can bind to N-linked 
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